Shipments come on the heels of a severe flu season and record deaths in children.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The rate also increased with each additional underlying medical condition.
Other trends included worrisome rises in tuberculosis, measles, and pertussis.
The death-rate ratio of adults aged 70 years and older and children younger than 5 years climbed globally, with the Western Pacific Region experiencing the largest increase.
Though hospitalizations and other markers trended lower, the CDC received reports of 17 more pediatric flu deaths.
Sixteen more pediatric flu deaths were reported, as hospitalizations and outpatient visits remain high.
While influenza B patients had better short-term outcomes, they experienced higher-than-expected rates of hospitalization, ICU admission, and death.
Twelve more pediatric flu deaths were reported, mostly caused by the H1N1 strain, raising the season's total to 98.
The group also recommended two vaccine strains for pandemic preparedness, one for the H5N1 2.3.2.1a clade and another targeting the reemerging H5N6 2.3.4.4h clade.
The study involved 68 US children who died from seasonal flu this season.
The Vaccines and Related Biological Products Advisory Committee was scheduled to meet March 13 to select virus strains for the 2025-26 flu vaccine.
